Lung Cancer in New Zealand: Patterns of Secondary Care and Implications for Survival Wendy Stevens, MBBS, Graham Stevens, MD, FRANZCR, John Kolbe, MBBS,

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP, John M. Alvarez,

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Stephen R. Broderick, MD, MPHS

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma Dean A. Fennell, PhD, FRCP,

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer David R. Spigel,

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Electronic Updates for JTO Readers

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

George Blumenschein, MD, John V. Heymach, MD, PhD

Variations in Receipt of Curative-Intent Surgery for Early-Stage Non–Small Cell Lung Cancer (NSCLC) by State Helmneh M. Sineshaw, MD, MPH, Xiao-Cheng.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

E-Cigarettes and Cancer Patients

Is tissue the issue? Brian E. Louie, MD, MHA, MPH, FRCSC, FACS

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

Erratum Journal of Thoracic Oncology

Stephen R. Broderick, MD, MPHS

Ayman O. Soubani, MD, John C. Ruckdeschel, MD

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

The Number of Pulmonary Metastases: Influence on Practice and Outcome

S768I Mutation in EGFR in Patients with Lung Cancer

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Should Large Cell Neuroendocrine Lung Carcinoma be Classified and Treated as a Small Cell Lung Cancer or with Other Large Cell Carcinomas? John M. Varlotto,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Uma M. Sachdeva, MD, PhD, Daniela Molena, MD

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Gaps in Optimal Care for Lung Cancer

Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada Christopher M. Booth,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Ethnic Differences in the Management of Lung Cancer in New Zealand

Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J

European Lung Cancer Conference (ELCC) 2016 Organisation

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Epidemiology of Thymoma and Associated Malignancies

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Survival Benefits from Follow-Up of Patients with Lung Cancer: A Systematic Review and Meta-Analysis Lynn Calman, PhD, Kinta Beaver, PhD, Daniel Hind,

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Mark A. Socinski, MD Journal of Thoracic Oncology

Presentation transcript:

Lung Cancer in New Zealand: Patterns of Secondary Care and Implications for Survival Wendy Stevens, MBBS, Graham Stevens, MD, FRANZCR, John Kolbe, MBBS, FRACP, Brian Cox, MB, ChB, PhD, FAFPHM Journal of Thoracic Oncology Volume 2, Issue 6, Pages 481-493 (June 2007) DOI: 10.1097/JTO.0b013e31805fea3a Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 (A) Influence of age on anticancer referral, anticancer treatment, and curative intent for (i) cases with either a histological diagnosis of NSCLC or a clinicoradiological diagnosis of lung cancer, and (ii) cases with SCLC. (B) Association of patient age (all cases) with any potentially relevant comorbidity, respiratory disease, cardiovascular disease, or other comorbidity (i.e., other than respiratory or cardiovascular disease). Journal of Thoracic Oncology 2007 2, 481-493DOI: (10.1097/JTO.0b013e31805fea3a) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions